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TCT-233
First-In-Man IVUS Findings of the Prohealing PROTEXTM Coronary Stent
System for the Treatment of Coronary Artery Disease
Kenji Sakata1, Daisaku Nakatani1, Katsuhisa Waseda1, Paul G Yock1, Yasuhiro
Honda1, Peter J Fitzgerald1, William Wijns2
1Stanford University Medical Center, Stanford, CA; 2Cardiovascular Center Aalst,
Aalst, Belgium
Background: The PROTEX system integrates a cobalt alloy stent platform with
prohealing extracellular matrix coating that facilitates rapid coverage of the stent
surface by endothelial cells from the tissue and/or endothelial progenitor cells in the
blood stream. This study aimed to evaluate vessel response to this novel device in
human coronary lesions as assessed by IVUS.
Methods: In a first-in-man, prospective, multicenter, single-arm trial of PROTEX,
serial (baseline and 6 months) IVUS was performed in 38 patients. In addition to the
standard IVUS variables, a neointima-free frame ratio (number of frames without
neointima/total frame number) was calculated to assess gross coverage of struts. Cross-
sectional (cross-sectional narrowing: CSN) and longitudinal severity indices (% stent
length with CSN >60%: IH60) of lumen encroachment by neointima were also
assessed.
Results: Overall, vessel behind the stent showed a slight shrinkage during follow-up,
and no case had excessive positive remodeling or late-acquired incomplete stent
apposition. The neointima-free frame ratio was 1.4%, indicating almost no exposed
stent struts at 6 months. In cases with significant lumen encroachment (max CSN
>60%), the longitudinal severity index was 13.4%, representing focal neointimal
accumulation.
IH60 was defined as percent stent length with CSN >60%
CSN; cross sectional narrowing, ISA; incomplete stent apposition
Conclusion: First-in-man IVUS results of PROTEX demonstrated favorable vessel
responses with nearly complete tissue coverage of struts within 6 months. Possible
synergy of this prohealing stent coating and antiproliferative agents may warrant
investigations.
TCT-234
Vascular Healing After Endothelial Progenitor Cell Capturing Stent
Implantation at 30 days
Tuomas Lehtinen1, 2, Tuomas Kiviniemi1, 2, Antti Ylitalo2, Jussi Mikkelsson2, Pasi P
Karjalainen2
1Turku University Hospital, Turku, Finland; 2Satakunta Central Hospital, Pori,
Finland
Background: As an alternative to DES, a novel antibody-coated endothelial progenitor
cell capturing (EPC) Genous (OrbusNeich Medical GmbH, Wiesbaden, Germany) stent
has been developed, which has shown good results in unselected patiens. The capture
of circulating endothelial progenitor cells promotes rapid endothelialization of the stent,
which in turn allows shorter duration of dual-antiplatelet treatment. Optical coherence
tomography (OCT) has become the method of choice for evaluating stent
endothelialization and vascular healing.
Methods: We analyzed the percentage of stent strut endothelial cell coverage (binary
strut coverage) and stent apposition using optical coherence tomography (OCT) and
assessed the reactivity of the microcirculation using coronary flow reserve (CFR) by
transthoracic echocardiography after implantation of EPC stents. A total of 20 patients
with a lesion in LAD were enrolled and OCT and CFR were performed at 30 days after
stent implantation.
Results: The binary stent strut coverage was 94.8 %. No thrombi were detected and
the percentage of malapposed stent struts was 2.4 %. The mean NIH thickness was
108 ± 96 μm and NIH% 8.9 ± 7.4 %. Mean CFR was 2.5 ± 0.2. Two patients had
abnormal CFR < 2.0 (1 restenosis and 1 de novo lesion in the target vessel).
Table. Optical tomographic measurements
Conclusion: Evaluated with OCT and CFR, the Genous stent showed favorable healing
properties with rapid endothelialization, low NIH% area, few malapposed struts and
adequate vasodilation response at 30 days excluding patient with restenosis.
TCT-235
Evaluation of Neointimal Healing of EPC-Capturing Sirolimus-Eluting
COMBO Stent by Optical Coherence Tomography: The EGO-COMBO Pilot
Study (interim results)
Stephen W L Lee, Simon C Lam, Kelvin K Chan, Michael K Wong, Frankie C Tam,
Anthony Y Wong, Arthur Yung, Yui-Ming Lam, Shun-Ling Kong, Raymond H Chan
Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, Hong Kong
Background: COMBO Stent (OrbusNeich Medical, FL, USA) is a hybrid version of
the endothelial progenitor cell (EPC) capturing GENOUS Stent, with an additional
abluminal 5 μg/mm sirolimus coating, about ½ the dose of current sirolimus-eluting
stent but with a similar release profile (about 90% of the drug released by 35 days) via
a Surmodics SynBiosys™ bio-degradable polymer, aiming at optimal neointimal
suppression similar to other DES while retaining the EPC capturing benefit (envisaged
better endothelialization and less late stent thrombosis) as reported in animal models.
Such combined benefits were evaluated clinically in this Study.
Methods: In this prospective, single center, pilot study, 60 patients treated by COMBO
Stent were randomised to 4 monthly groups (in 1:2:2:1 ratio). OCT was performed
sequentially at baseline post-stenting, at early follow-ups in 4 groups at 2nd, 3rd, 4th,
and 5th month (for early neointimal healing), and at 9 months (for OCT late loss).
Independent OCT core laboratory performed the covered strut % and neointima
analyses, while in-house analyses further stratified the early strut coverage into 6
categories.
Results: To date, all 60 patients (30% diabetic, 87 COMBO stents implanted) were
enrolled; 40 had the first OCT follow up. A total of 7004 frames and 60069 struts were
analyzed. The mean percentage of covered struts (with proper apposition) was 74.4%,
84.0%, 87.4% & 95.6%, p=0.014, 0.226, & 0.046, from 2nd to 5th monthly group,
respectively (refer to Figure). No MACE was recorded. Study Limitations: (1) no other
DES control arm & (2) OCT classification of early strut coverage requires further
validation.
Conclusion: These early OCT follow-up data suggest the possible healing profile of
the new EPC-capturing COMBO DES, with near 100% strut coverage by 140 days.
Nine months follow-up data are pending. Clinical data on larger patient population are
needed to verify these promising imaging results.
TCT-236
Twelve-Month Clinical Efficacy and Safety of Zotarolimus- versus Everolimus-
Eluting Stents in a Series of Asian Population
SunWon Kim, Seung Woon Rha, Byoung Geol Choi, Amro Elnagar, Sung Il Im, Jin
Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju
Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Korea University Guro Hospital, Seoul, Republic of Korea
Background: Recently, newer generation drug-eluting stents (DESs) have been widely
used with improved performance and safety. However, there have been limited data
comparing angiographic and clinical outcomes of individual newer generation DESs
in real world clinical practice, specifically in Asian population.
Methods: A total of 608 patients (pts) underwent percutaneous coronary intervention
(PCI) with Zotarolimus-eluting stents (ZES group; Endeavor ResoluteTM, n=238 pts)
and Everolimus-eluting stents (EES group; PromusTM or XienceTM n=370 pts) were
enrolled for this study. Angiographic outcomes at 6 months and major clinical outcomes
up to 12 months were compared.
Results: There were no significant differences in baseline clinical characteristics
between the two groups. At 6 months, angiographic outcomes were similar between
the two groups. At 12 months, there was a trend toward higher incidence of non-target
lesion revascularization (TLR) target vessel revascularization (TVR) in the EES group;
however other major clinical outcomes including mortality, Q-wave myocardial
infarction (MI), repeat PCI and major adverse cardiac events (MACEs) were similar
between the two groups up to 12 months (Table)
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Conclusion: In our study, both new generation DESs, ZES and EES were similarly
effective and safe up to 1 year following routine PCI in Asian population
TCT-237
Two-Year Outcomes of a Propensity-Matched Comparison of the ION and
TAXUS Liberté Paclitaxel-Eluting Stents
Dean J Kereiakes1, Louis A Cannon2, John A Ormiston3, Hong Wang4, Paul L
Underwood4, Keith D Dawkins4
1The Christ Hospital Heart and Vascular Center/The Lindner Center for Research
and Education, Cincinnati, OH; 2The Cardiac & Vascular Research Center of
Northern Michigan, Northern Michigan Regional Hospital, Petoskey, MI; 3Mercy
Angiography, Mercy Hospital, Auckland, New Zealand; 4Boston Scientific
Corporation, Marlborough, MA
Background: The TAXUS Element (ION) paclitaxel-eluting stent (PES) uses the same
polymer and drug as the TAXUS Liberté PES, but with a novel thin (81μM) strut
platinum chromium metal alloy cell design. We present 2-year data comparing clinical
outcomes between the ION and TAXUS Liberté PES.
Methods: Patient-level data from 2298 subjects treated with PES were pooled from
the TAXUS ATLAS (TAXUS Liberté Stent) and PERSEUS (ION Stent) trials and
propensity matched 1:1 to adjust for significant baseline differences.
Results: Two-year MACE was significantly lower in the ION versus the TAXUS
Liberté group, with and without propensity matching (Table), driven largely by a
reduction in non-Q-wave MI. Numerical reductions in non-Q-wave MI were seen in
both the periprocedural (2.1% vs. 1.3%, P=0.12 unadjusted; 2.4% vs. 0.8%, P=0.02
matched) and discharge – 2 year timeframes (1.3% vs. 0.5%, P=0.07 unadjusted; 1.2%
vs. 0.6%, P=0.28 matched). Non-Q-wave MI was significantly lower with ION in
patients treated with single stents (3.1% vs. 1.4%, P=0.01 unadjusted; 3.4% vs. 1.4%,
P=0.02 matched) but not in patients treated with multiple stents, although sample sizes
were small (5.9% [N=85] vs. 5.6% [N=90], P=0.94 unadjusted; 7.7% [N=39] vs. 1.8%
[N=55], P=0.17 matched). Stent thrombosis (ARC definite/probable) was numerically
less frequent following ION use.
Conclusion: In this exploratory post hoc analysis, ION was associated with lower 2-
year MACE than TAXUS Liberté, driven mainly by reduced non-Q-wave MI. These
differences may be explained by thinner struts and modified cell design in the ION
stent, although evolution in adjunctive therapies and stenting technique may also
contribute.
TCT-238
Proximal & Distal Maximal Luminal Diameters (Dmax) as a Guide to
Appropriate Deployment of the Everolimus-Eluting Bioresorbable Vascular
Scaffold: A Substudy of the ABSORB Cohort B & On-Going ABSORB
EXTEND Single Arm Study
Vasim Farooq1, Josep Gomez-Lara1, Salvatore Brugaletta1, Bill D Gogas1, Hector M
Garcia Garcia1, Yoshinobu Onuma1, Robert Jan van Geuns1, Antonio Bartorelli2,
Robert Whitbourn3, Alexandre Abizaid4, Patrick W Serruys1
1ThoraxCenter, ERASMUS MC, Rotterdam, Netherlands; 2Centro Cardiologico
Monzino, IRCCS, Institute of Cardiology, Milan, Italy; 3St. Vincent’s Hospital,
Fitzroy Victoria, Australia, Victoria, Australia; 4Instituto Dante Pazzanese de
Cardiologia, Sao Paulo, Brazil, Sao Paulo, Brazil
Background: Due to the limited distensibility of the everolimus-eluting bioresorbable
vascular scaffold (ABSORB) compared to metallic platform stents, quantitative
coronary arteriography (QCA) is a mandatory requirement for ABSORB deployment
in ABSORB EXTEND. Visual assessment of vessel size in the ABSORB Cohort B
study often lead to under (Fig.) & over-sizing of the 3mm ABSORB in coronary vessels
(recommended vessel diameter ≥2.5-≤3.3mm), with an increased risk of spontaneous
incomplete scaffold apposition post deployment. We report whether mandatory QCA
assessment of vessel size pre-implantation utilising the Dmax & established
interpolated reference vessel diameter (RVD) measurements has improved
device/vessel sizing.
Methods: Pre-implantation post-hoc QCA analyses of all 101 patients from ABSORB
Cohort B (102 lesions) & first consecutive 101 patients (108 lesions) from ABSORB
EXTEND were undertaken by an independent corelab; all patients had a 3mm
ABSORB implanted. Comparative analyses were performed.
Results: Within ABSORB Cohort B a greater no. of over-sized vessels (>3.3mm) were
identified utilizing the Dmax compared to the RVD (17 vessels, 16.7% vs. 3 vessels,
2.9%; p=0.002). Comparative analyses demonstrated a greater no. of appropriate vessel
size selection (75 vessels, 69.4% vs. 48 vessels, 47.1%; p=0.001), a trend towards a
reduction in implantation in small (<2.5mm) vessels (29 vessels, 26.9% vs. 40 vessels,
39.2%; p=0.057) & a significant decrease in the implantation in large (>3.3 mm)
vessels (4 vessels, 3.7% vs. 17 vessels, 16.7%; p=0.002) in ABSORB EXTEND.
Bland–Altman plots suggested a good agreement between operator/corelab assessed
Dmax measurements.
3mm BVS implanted in vessel with Dmax 4.42mm
Conclusion: The introduction of mandatory Dmax measurements of vessel size prior
to ABSORB implantation significantly reduced the undersizing of the 3.0mm ABSORB
in large vessels validating the use of this technique in vessel sizing prior to ABSORB
implantation.
TCT-239
FINAL RESULTS OF THE SVELTE TRIAL WITH THE NOVEL ACROBAT
BALLOO-EXPANDABLE SOAW CORONARY SYSTEM
Jose De Ribamar Costa1, Alexandre Abizaid1, Pieter Stela3, Juan Granada4, Andres
Fernandes4, Fausto Feres1, Patrick Serruys2
1Instituto Dante Pazzanese / HCOR, São Paulo, Brazil; 2Eramus University,
Rotterdam, Netherlands; 3Utrech Medical Center, Utrech, Netherlands; 4Corbic,
Bogota, Colombia
Background: Direct stenting (DS) may potentially reduce vessel trauma,
“geographical miss”, prevent distal embolization and save time/money during PCI.
However, DS is currently performed in < 50%. Among the reasons to pre-dilate, vessel
anatomy (tortuosity and amount of calcification) plays a central role in the operator’s
decision.The Acrobat SOAW (Stent-On-A-Wire) coronary system combines a very-
thin (81 μ) balloon-expandable, Cro-Co stent mounted on a delivery system with a
0.012” integrated guidewire tip (distance from the tip of the wire to the stent is 22mm).
We sought to determine the efficacy of this novel device.
Methods: SVELTE trial is a multicenter(Brazil, Netherlands and Colombia),
prospective, non-randomized, single-arm study of the Acrobat SOAW for the treatment
of de novo coronary lesions no longer than 18mm and located in native vessels of 2.5
to 3.5mm. DS was highly recommended. Patients were oriented to stay on dual anti-
platelet regimen for at least 1 month. Main exclusion criteria were PCI in the setting
www.JACC.TCTAbstracts2011
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